Document is current
Any future updates will be listed below
-
Authors
Lathrop, Stephanie K.
Clark, Jordan J.
Siram, Karthik
Andreata-Santos, Robert
Yong, Jeremy
Tee, Rebekah D.
Davison, Clara J.
Singh, Gagandeep
Burkhart, David
Krammer, Florian
Evans, Jay T.
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (75N93019C00045, 75N93021C00014, 75N93019C00045, 75N93021C00014, 75N93021C00014, 75N93019C00045, 75N93019C00045, 75N93021C00014, 75N93019C00045, 75N93021C00014, 75N93019C00045)
- License Information
-
More Information
Article History
Received: 6 March 2024
Accepted: 9 May 2024
First Online: 6 August 2024
Competing interests
: D.J.B., J.T.E. and R.T. are employees of and/or shareholders of Inimmune Corp., which owns INI-2002 and holds an exclusive license for INI-4001. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines influenza virus vaccines and influenza virus therapeutics which list Florian Krammer as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. Florian Krammer is co-founder and scientific advisory board member of Castlevax. Florian Krammer has consulted for Merck, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures, GSK, Gritstone and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza vaccine development.
